ANALYST RECOMMENDATIONS : Alphabet, Amgen, GSK, Moderna, Smiths Group...

Every morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated during the session. This information can be used to shed light on movements in certain stocks or on market sentiment towards a company.

• Alphabet: UBS downgrades from buy to neutral but raises its target from 123 to 132 USD.
• Amgen: Argus remains Buy, but has lowered its target from USD 270 to USD 260.
• BT Group: UBS downgrades from neutral to sell with a target of GBp 120.
• Dechra Pharmaceuticals: Stifel downgrades to hold from buy. PT up 6.7% to 3,875 pence.
• GSK: Intron Health downgrades its Buy recommendation to Hold with a target of GBp 1450.
• Informa: Berenberg resumes its monitoring with a Buy recommendation and a GBp 820 target.
• Kellogg: Goldman Sachs upgrades to buy from neutral. PT up 19% to $78.
• Moderna: UBS upgrades its opinion from neutral to buy but lowers its target from 221 to 191 USD.
• Roper: Jefferies initiated coverage with a recommendation of buy. PT up 15% to $530.
• Smiths Group: HSBC initiates coverage with a hold recommendation and a target of GBp 1860.
• Stewart Information: Keefe, Bruyette & Woods downgrades to market perform from outperform. PT up 7.3% to $45.